Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs

ISSN： 1750-743X

Source： Immunotherapy, Vol.5, Iss.12, 2013-12, pp. : 1347-1355

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy

By Gerritsen Winald Sharma Padmanee

Journal of Clinical Immunology, Vol. 32, Iss. 1, 2012-02 ,pp. : 25-35

Springer Publishing Company

Access to resources Recommend Favorite

The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients

By Komiya

Molecular and Clinical Oncology, Vol. 1, Iss. 2, 2013-01 ,pp. : 257-262

Spandidos Publications

Access to resources Recommend Favorite

Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials

Molecular and Clinical Oncology, Vol. 2, Iss. 6, 2014-01 ,pp. : 1182-1188

Spandidos Publications

Access to resources Recommend Favorite

Targeted-Chemotherapy of Cancer with Monoclonal Antibodies

By Weltman Joel K.

Allergy and Asthma Proceedings, Vol. 3, Iss. 2, 1982-0 ,pp. : 315-317

OceanSide Publications, Inc

Access to resources Recommend Favorite

Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs

By Hefta L.J.F. Neumaier M. Shively J.E.

Immunotechnology, Vol. 4, Iss. 1, 1998-06 ,pp. : 49-57

Elsevier

Access to resources Recommend Favorite